BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26484208)

  • 1. Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis.
    Martinaud C; Desterke C; Konopacki J; Vannucchi AM; Pieri L; Guglielmelli P; Dupriez B; Ianotto JC; Boutin L; Lataillade JJ; Le Bousse-Kerdilès MC
    Genom Data; 2015 Sep; 5():1-2. PubMed ID: 26484208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary myelofibrosis and the "bad seeds in bad soil" concept.
    Le Bousse-Kerdilès MC
    Fibrogenesis Tissue Repair; 2012; 5(Suppl 1):S20. PubMed ID: 23259918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis.
    Desterke C; Martinaud C; Ruzehaji N; Le Bousse-Kerdilès MC
    Mediators Inflamm; 2015; 2015():415024. PubMed ID: 26640324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Focus on Osteosclerotic Progression in Primary Myelofibrosis.
    Spampinato M; Giallongo C; Romano A; Longhitano L; La Spina E; Avola R; Scandura G; Dulcamare I; Bramanti V; Di Rosa M; Vicario N; Parenti R; Li Volti G; Tibullo D; Palumbo GA
    Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33477816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice.
    Ozono Y; Shide K; Kameda T; Kamiunten A; Tahira Y; Sekine M; Akizuki K; Nakamura K; Iwakiri H; Sueta M; Hidaka T; Kubuki Y; Yamamoto S; Hasuike S; Sawaguchi A; Nagata K; Shimoda K
    Leukemia; 2021 Feb; 35(2):454-467. PubMed ID: 32472085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesenchymal stem cells in myeloproliferative disorders - focus on primary myelofibrosis.
    Selicean SE; Tomuleasa C; Grewal R; Almeida-Porada G; Berindan-Neagoe I
    Leuk Lymphoma; 2019 Apr; 60(4):876-885. PubMed ID: 30277128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion.
    Tripodo C; Sangaletti S; Guarnotta C; Piccaluga PP; Cacciatore M; Giuliano M; Franco G; Chiodoni C; Sciandra M; Miotti S; Calvaruso G; Carè A; Florena AM; Scotlandi K; Orazi A; Pileri SA; Colombo MP
    Blood; 2012 Oct; 120(17):3541-54. PubMed ID: 22955913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the extracellular matrix in primary myelofibrosis.
    Leiva O; Ng SK; Chitalia S; Balduini A; Matsuura S; Ravid K
    Blood Cancer J; 2017 Feb; 7(2):e525. PubMed ID: 28157219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.
    Rambaldi B; Diral E; Donsante S; Di Marzo N; Mottadelli F; Cardinale L; Dander E; Isimbaldi G; Pioltelli P; Biondi A; Riminucci M; D'Amico G; Elli EM; Pievani A; Serafini M
    Ann Hematol; 2021 Jan; 100(1):105-116. PubMed ID: 33089365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGF-β signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche.
    Yao JC; Oetjen KA; Wang T; Xu H; Abou-Ezzi G; Krambs JR; Uttarwar S; Duncavage EJ; Link DC
    J Clin Invest; 2022 Jun; 132(11):. PubMed ID: 35439167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis.
    Verstovsek S; Manshouri T; Pilling D; Bueso-Ramos CE; Newberry KJ; Prijic S; Knez L; Bozinovic K; Harris DM; Spaeth EL; Post SM; Multani AS; Rampal RK; Ahn J; Levine RL; Creighton CJ; Kantarjian HM; Estrov Z
    J Exp Med; 2016 Aug; 213(9):1723-40. PubMed ID: 27481130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The regulation of normal and neoplastic hematopoiesis is dependent on microenvironmental cells.
    Kaushansky K; Zhan H
    Adv Biol Regul; 2018 Aug; 69():11-15. PubMed ID: 29970351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis.
    Leimkühler NB; Gleitz HFE; Ronghui L; Snoeren IAM; Fuchs SNR; Nagai JS; Banjanin B; Lam KH; Vogl T; Kuppe C; Stalmann USA; Büsche G; Kreipe H; Gütgemann I; Krebs P; Banz Y; Boor P; Tai EW; Brümmendorf TH; Koschmieder S; Crysandt M; Bindels E; Kramann R; Costa IG; Schneider RK
    Cell Stem Cell; 2021 Apr; 28(4):637-652.e8. PubMed ID: 33301706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence.
    Lataillade JJ; Pierre-Louis O; Hasselbalch HC; Uzan G; Jasmin C; Martyré MC; Le Bousse-Kerdilès MC;
    Blood; 2008 Oct; 112(8):3026-35. PubMed ID: 18669872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis.
    Martinaud C; Desterke C; Konopacki J; Pieri L; Torossian F; Golub R; Schmutz S; Anginot A; Guerton B; Rochet N; Albanese P; Henault E; Pierre-Louis O; Souraud JB; de Revel T; Dupriez B; Ianotto JC; Bourgeade MF; Vannucchi AM; Lataillade JJ; Le Bousse-Kerdilès MC
    Cancer Res; 2015 Nov; 75(22):4753-65. PubMed ID: 26404004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6.
    Rontauroli S; Norfo R; Pennucci V; Zini R; Ruberti S; Bianchi E; Salati S; Prudente Z; Rossi C; Rosti V; Guglielmelli P; Barosi G; Vannucchi A; Tagliafico E; Manfredini R
    Oncotarget; 2017 Mar; 8(13):21380-21397. PubMed ID: 28423484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis.
    Bianchi E; Ruberti S; Rontauroli S; Guglielmelli P; Salati S; Rossi C; Zini R; Tagliafico E; Vannucchi AM; Manfredini R
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28098757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
    Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
    Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis.
    Bacher U; Asenova S; Badbaran A; Zander AR; Alchalby H; Fehse B; Kröger N; Lange C; Ayuk F
    Clin Exp Med; 2010 Sep; 10(3):205-8. PubMed ID: 19629639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients.
    Ruberti S; Bianchi E; Guglielmelli P; Rontauroli S; Barbieri G; Tavernari L; Fanelli T; Norfo R; Pennucci V; Fattori GC; Mannarelli C; Bartalucci N; Mora B; Elli L; Avanzini MA; Rossi C; Salmoiraghi S; Zini R; Salati S; Prudente Z; Rosti V; Passamonti F; Rambaldi A; Ferrari S; Tagliafico E; Vannucchi AM; Manfredini R
    Leukemia; 2018 Feb; 32(2):438-449. PubMed ID: 28745329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.